Ronald J. Wapner, M.D. Joins CombiMatrix Scientific Advisory Board
Internationally Known Physician, Researcher in Reproductive Genetics
IRVINE, Calif., April 19, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that Ronald J. Wapner, M.D., an internationally renowned physician and researcher specializing in reproductive genetics, has joined the CombiMatrix Scientific Advisory Board.
Dr. Wapner is the Vice Chair for Research in Obstetrics and Gynecology for Columbia University Medical Center and Director of Reproductive Genetics. He pioneered the development of chorionic villus sampling (CVS) and multi-fetal reduction, and has authored more than 250 publications.
Dr. Wapner is also an active investigator in the area of Maternal-Fetal Medicine and the principal investigator for the recently completed National Institute of Child Health and Human Development (NICHD)-sponsored prospective, multi-center study comparing chromosomal microarray testing to karyotyping. The study results indicate that chromosomal microarray testing is superior to karyotyping, and will be recommended as the new standard of care for prenatal diagnosis.
"Dr. Wapner is a key opinion leader in prenatal testing and genetics," said CombiMatrix CEO Judd Jessup. "We believe that the NICHD-sponsored study of microarray testing may be the single-most important commercial catalyst for the prenatal diagnosis of chromosome abnormalities in the last decade. We plan on becoming a very important player in the reproductive and developmental genetics marketplace and his input on our Scientific Advisory Board will be invaluable."
Dr. Wapner received a Bachelor of Science degree from the University of Pittsburgh and his M.D. degree from Jefferson Medical College in Philadelphia. He is a member of the editorial board of Prenatal Diagnosis.
About CombiMatrix Corporation
CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory which offers DNA-based testing services to the prenatal, pediatric and oncology markets. The Company performs genetic testing utilizing Microarray, FISH, PCR and G-Band Chromosome Analysis. CMDX offers prenatal and pediatric testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was also the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors, including breast, colon, lung, prostate and brain tumors, available to oncology patients and medical professionals. Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding projected results of operations and management's future business, operational and strategic plans, test menu expansion, services and reports development and attracting greater prenatal genetic screening business. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, steadily increase the size of our customer rosters in both developmental medicine and oncology;our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; the ability of microarray technology to become the standard of care; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
CONTACT: Company Contact:
R. Judd Jessup
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Investor Relations Contact:
Matthew H. Clawson
Partner, Allen & Caron, Inc.
Tel (949) 474-4300